SEC Form 4 · accession 0001209191-17-053055

KYNTRA BIO, INC. · KYNB

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Thomas B Neff

Officer — Chief Executive Officer · Director

Period of report

Sep 13, 2017

Accepted (ET)

Sep 15, 2017 · 6:37 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000921299

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2	Sep 13, 2017	S	4,900	$50.33	D	3,297,655	D
Common Stock^F1,F3	Sep 13, 2017	S	11,500	$51.52	D	3,286,155	D
Common Stock^F1,F4	Sep 13, 2017	S	2,500	$52.13	D	3,283,655	D
Common Stock^F1	Sep 13, 2017	S	318	$51.75	D	133,884	I	By Family Partnership
Common Stock^F1	Sep 13, 2017	S	100	$51.275	D	133,784	I	By Family Partnership
Common Stock^F1,F5	Sep 14, 2017	S	1,500	$50.89	D	3,282,155	D
Common Stock^F1,F6	Sep 14, 2017	S	12,000	$51.99	D	3,270,155	D
Common Stock^F1,F7	Sep 14, 2017	S	5,400	$52.47	D	3,264,755	D
Common Stock^F1	Sep 14, 2017	S	318	$52.075	D	133,466	I	By Family Partnership
Common Stock^F1	Sep 14, 2017	S	100	$51.55	D	133,366	I	By Family Partnership
Common Stock	holding	—	—		—	20,000	I	By Spouse
Common Stock^F8	holding	—	—		—	60,946	I	See footnote

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses

F1Shares sold pursuant to a 10b5-1 plan.
F2The shares were sold at prices ranging from $49.60 to $50.50. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3The shares were sold at prices ranging from $50.95 to $51.90. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4The shares were sold at prices ranging from $51.95 to $52.30. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F5The shares were sold at prices ranging from $50.30 to $51.25. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F6The shares were sold at prices ranging from $51.35 to $52.325. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F7The shares were sold at prices ranging from $52.35 to $52.625. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F8The shares are held by BioGrowth Partners, LP. The reporting person is the sole general partner of BioGrowth Partners, LP and has sole voting and dispositive power over the shares held by BioGrowth Partners, LP.